Twist Bioscience Corporation
TWSTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTwist Bioscience Corporation manufactures and sells synthetic DNA-based products. The $8.03B market capitalization puts TWST squarely in mid-cap range for its industry. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Market Cap
$8.03B
Beta
2.22
P/E (TTM)
—
P/E (Fwd)
-202.20
EPS (TTM)
$-2.23
EPS (Fwd)
$-0.63
ROE
-29.6%
ROA
-13.1%
Cash
$166.8M
Total Debt
$108.6M
Free CF
-$64.8M
52W Change
416.2%
Annual Financials
Cash vs Debt
Where TWST stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TWST finished 77.84% above its 150-day moving average ($73.66) and 105.49% above its 200-day moving average ($63.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TWST overbought or oversold?
At the September 3, 2026 close, TWST's RSI(14) was 52.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Twist Bioscience Corporation holds $166.8M in cash against $108.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$64.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -29.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $203.6M (2022) to $376.6M (2025), reflecting a 85% increase over the period.
A beta of 2.22 means TWST is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Twist Bioscience Corporation's trajectory.